Biofabri and TBVI have signed a contract with the European Health and Digital Executive Agency (HaDEA) under the EU4Health Programme to accelerate the final development of the MTBVAC vaccine. MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.
Through the EU4Health Programme, HaDEA’s support will accelerate the final stages of the clinical development of MTBVAC by supporting a Phase 3 clinical trial in neonates, which is currently well underway in various African countries. The trial aims to evaluate the protective efficacy, safety and immunogenicity of a single dose of MTBVAC administered by intradermal route in healthy HIV-unexposed and HIV-exposed neonates. A safe, effective and accessible new TB vaccine such as MTBVAC will be essential to stop the development and spread of both drug sensitive and drug-resistant TB.
Please read the Press release: Biofabri and TBVI sign contract with HaDEA